Wyeth taps Cost to head corporate affairs dept.

Wyeth hired Timothy Cost to head its corporate affairs department, replacing Marily Rhudy, who is retiring.

Cost joins the company from Philadelphia food services firm Aramark, where he was EVP, corporate affairs. He becomes senior vice president, corporate affairs, reporting to president and CEO Bernard Poussot. 

Prior to joining Aramark in 2003, he had spent many years in the pharmaceutical industry, serving as SVP, communications and strategy for Centocor, VP, investor relations and corporate intelligence for Bristol-Myers Squibb and SVP, corporate affairs for Pharmacia. Poussot said in a statement: “His extensive and broad experience, especially in the biotechnology and pharmaceutical sectors, will help us as we continue to deliver innovative new products and navigate the changing business environment.”

Rhudy joined Wyeth in 1993 as assistant VP, professional relations for pharmaceuticals and worked her way up while building the public affairs function, rising to SVP, corporate public affairs in 2004.

She had previously served on the White House Health Care Professionals Task Force on Health Care Reform.

Poussot credited Rhudy with having “built an outstanding public affairs team that has forged strong external relationships to raise the level of awareness of Wyeth's contributions to healthcare.” 
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.